Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy

Human Genetics

Volumn 135, Issue 9, 2016, Pages 1029-1040

  Robinson Hamm, Jacqueline N ^a,b   Gersbach, Charles A ^a,b,c  

^a USA   (United States)

^b DUKE UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN; VIRUS VECTOR;

CELL THERAPY; DUCHENNE MUSCULAR DYSTROPHY; EXON SKIPPING; HUMAN; MUSCLE STRENGTH; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME; ANIMAL; EXON; GENE THERAPY; GENETICS; MOUSE; MUSCULAR DYSTROPHY, DUCHENNE;

ANIMALS; DYSTROPHIN; EXONS; GENETIC THERAPY; HUMANS; MICE; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 84982284230     PISSN: 03406717     EISSN: 14321203     Source Type: Journal    
DOI: 10.1007/s00439-016-1725-z     Document Type: Review

References (134)

1. Aartsma-Rus A, Ferlini A, Goemans N, Pasmooij AM, Wells DJ, Bushby K, Vroom E, Balabanov P (2014) Translational and regulatory challenges for exon skipping therapies. Hum Gene Ther 25:885–892
2. Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD, Partridge TA, Lu QL (2006) Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12:175–177
3. Aoki Y, Yokota T, Nagata T, Nakamura A, Tanihata J, Saito T, Duguez SM, Nagaraju K, Hoffman EP, Partridge T et al (2012) Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci U S A 109:13763–13768
4. Arnould S, Delenda C, Grizot S, Desseaux C, Paques F, Silva GH, Smith J (2011) The I-CreI meganuclease and its engineered derivatives: applications from cell modification to gene therapy. Protein Eng Design Selection PEDS 24:27–31
5. Athanasopoulos T, Graham IR, Foster H, Dickson G (2004) Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD). Gene Ther 11(Suppl 1):S109–S121
6. Athanasopoulos T, Foster H, Foster K, Dickson G (2011) Codon optimization of the microdystrophin gene for Duchene muscular dystrophy gene therapy. Methods Mol Biol 709:21–37
7. Baxter P (2010) Diagnosis and management of Duchenne muscular dystrophy. Dev Med Child Neurol 52:313
8. Bertoni C, Jarrahian S, Wheeler TM, Li Y, Olivares EC, Calos MP, Rando TA (2006) Enhancement of plasmid-mediated gene therapy for muscular dystrophy by directed plasmid integration. Proc Natl Acad Sci USA 103:419–424
9. Bish LT, Sleeper MM, Forbes SC, Wang B, Reynolds C, Singletary GE, Trafny D, Morine KJ, Sanmiguel J, Cecchini S et al (2012) Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping. Mol Ther 20:580–589
10. Bolukbasi MF, Gupta A, Wolfe SA (2016) Creating and evaluating accurate CRISPR-Cas9 scalpels for genomic surgery. Nat Methods 13:41–50
11. Bostick B, Yue YP, Lai Y, Long C, Li DJ, Duan DS (2008) Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice. Hum Gene Ther 19:851–856
12. Bostick B, Shin JH, Yue YP, Duan DS (2011) AAV-microdystrophin therapy improves cardiac performance in aged female mdx mice. Mol Ther 19:1826–1832
13. Bostick B, Shin JH, Yue Y, Wasala NB, Lai Y, Duan D (2012) AAV micro-dystrophin gene therapy alleviates stress-induced cardiac death but not myocardial fibrosis in >21-m-old mdx mice, an end-stage model of Duchenne muscular dystrophy cardiomyopathy. J Mol Cell Cardiol 53:217–222
14. Chapdelaine P, Pichavant C, Rousseau J, Paques F, Tremblay JP (2010) Meganucleases can restore the reading frame of a mutated dystrophin. Gene Ther 17:846–858
15. Chu VT, Weber T, Wefers B, Wurst W, Sander S, Rajewsky K, Kuhn R (2015) Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat Biotechnol 33:543–548
16. Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony K, Abbs S, Garralda ME, Bourke J, Wells DJ et al (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378:595–605
17. Cox DB, Platt RJ, Zhang F (2015) Therapeutic genome editing: prospects and challenges. Nat Med 21:121–131
18. Crapo RO, Casaburi R, Coates AL, Enright PL, MacIntyre NR, McKay RT, Johnson D, Wanger JS, Zeballos RJ, Bittner V et al (2002) ATS statement: guidelines for the six-minute walk test. Am J Resp Crit Care 166:111–117
19. Crow JF (2000) The origins, patterns and implications of human spontaneous mutation. Nat Rev Genet 1:40–47
20. Darabi R, Arpke RW, Irion S, Dimos JT, Grskovic M, Kyba M, Perlingeiro RCR (2012) Human ES- and iPS-derived myogenic progenitors restore DYSTROPHIN and improve contractility upon transplantation in dystrophic mice. Cell Stem Cell 10:610–619
21. Dittrich S, Tuerk M, Haaker G, Greim V, Buchholz A, Burkhardt B, Fujak A, Trollmann R, Schmid A, Schroeder R (2015) Cardiomyopathy in duchenne muscular dystrophy: current value of clinical, electrophysiological and imaging findings in children and teenagers. Klin Padiatr 227:225–231
22. D’Orsogna L, O’Shea JP, Miller G (1988) Cardiomyopathy of Duchenne muscular dystrophy. Pediatr Cardiol 9:205–213
23. Ehrhardt A, Engler JA, Xu H, Cherry AM, Kay MA (2006) Molecular analysis of chromosomal rearrangements in mammalian cells after phiC31-mediated integration. Hum Gene Ther 17:1077–1094
24. England SB, Nicholson LVB, Johnson MA, Forrest SM, Love DR, Zubrzyckagaarn EE, Bulman DE, Harris JB, Davies KE (1990) Very mild muscular-dystrophy associated with the deletion of 46-percent of dystrophin. Nature 343:180–182
25. Falzarano MS, Scotton C, Passarelli C, Ferlini A (2015) Duchenne muscular dystrophy: from diagnosis to therapy. Molecules 20:18168–18184
26. Farini A, Razini P, Erratico S, Torrente Y, Meregalli M (2009) Cell based therapy for Duchenne muscular dystrophy. J Cell Physiol 221:526–534
27. Farini A, Villa C, Manescu A, Fiori F, Giuliani A, Razini P, Sitzia C, Del Fraro G, Belicchi M, Meregalli M et al (2012) Novel insight into stem cell trafficking in dystrophic muscles. Int J Nanomed 7:3059–3067
28. Filareto A, Parker S, Darabi R, Borges L, Iacovino M, Schaaf T, Mayerhofer T, Chamberlain JS, Ervasti JM, McIvor RS et al (2013) An ex vivo gene therapy approach to treat muscular dystrophy using inducible pluripotent stem cells. Nat Commun 4:1549
29. Flanigan KM, Dunn DM, von Niederhausern A, Soltanzadeh P, Gappmaier E, Howard MT, Sampson JB, Mendell JR, Wall C, King WM et al (2009) Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum Mutat 30:1657–1666
30. Gaj T, Gersbach CA, Barbas CF 3rd (2013) ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 31:397–405
31. Gaj T, Epstein BE, Schaffer DV (2016) Genome engineering using adeno-associated virus: basic and clinical research applications. Mol Ther 24:458–464
32. Gersbach CA, Gaj T, Barbas CF 3rd (2014) Synthetic zinc finger proteins: the advent of targeted gene regulation and genome modification technologies. Acc Chem Res 47:2309–2318
33. Gibney E (2016) The science to look out for in 2016. Nature 529:14–15
34. Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, Heuvelmans N, Holling T, Janson AA, Platenburg GJ, Sipkens JA et al (2011) Systemic administration of PRO051 in Duchenne’s muscular dystrophy. N Engl J Med 364:1513–1522
35. Goemans N, Klingels K, van den Hauwe M, Boons S, Verstraete L, Peeters C, Feys H, Buyse G (2013a) Six-minute walk test: reference values and prediction equation in healthy boys aged 5 to 12 years. PLoS ONE 8:e84120
36. Goemans N, van den Hauwe M, Wilson R, van Impe A, Klingels K, Buyse G (2013b) Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids. Neuromuscular disorders: NMD 23:618–623
37. Gonzalez-Hilarion S, Beghyn T, Jia J, Debreuck N, Berte G, Mamchaoui K, Mouly V, Gruenert DC, Deprez B, Lejeune F (2012) Rescue of nonsense mutations by amlexanox in human cells. Orphanet journal of rare diseases 7:58
38. Goyenvalle A, Vulin A, Fougerousse F, Leturcq F, Kaplan JC, Garcia L, Danos O (2004) Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306:1796–1799
39. Goyenvalle A, Babbs A, Wright J, Wilkins V, Powell D, Garcia L, Davies KE (2012) Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping. Hum Mol Genet 21:2559–2571
40. Goyenvalle A, Griffith G, Babbs A, El Andaloussi S, Ezzat K, Avril A, Dugovic B, Chaussenot R, Ferry A, Voit T et al (2015) Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nat Med 21:270–275
41. Gregorevic P, Allen JM, Minami E, Blankinship MJ, Haraguchi M, Meuse L, Finn E, Adams ME, Froehner SC, Murry CE et al (2006) rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 12:787–789
42. Gregorevic P, Blankinship MJ, Allen JM, Chamberlain JS (2008) Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice. Mol Ther J Am Soc Gene Ther 16:657–664
43. Grimm T, Meng G, Liechti-Gallati S, Bettecken T, Muller CR, Muller B (1994) On the origin of deletions and point mutations in Duchenne muscular dystrophy: most deletions arise in oogenesis and most point mutations result from events in spermatogenesis. J Med Genet 31:183–186
44. Guiraud S, Aartsma-Rus A, Vieira NM, Davies KE, van Ommen GJB, Kunkel LM (2015) The Pathogenesis and Therapy of Muscular Dystrophies. Annu Rev Genom Hum G 16:281
45. Gussoni E, Pavlath GK, Lanctot AM, Sharma KR, Miller RG, Steinman L, Blau HM (1992) Normal dystrophin transcripts detected in duchenne muscular-dystrophy patients after myoblast transplantation. Nature 356:435–438
46. Heemskerk H, de Winter C, van Kuik P, Heuvelmans N, Sabatelli P, Rimessi P, Braghetta P, van Ommen GJ, de Kimpe S, Ferlini A et al (2010) Preclinical PK and PD studies on 2′-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol Ther J Am Soc Gene Ther 18:1210–1217
47. Helderman-van den Enden AT, Straathof CS, Aartsma-Rus A, den Dunnen JT, Verbist BM, Bakker E, Verschuuren JJ, Ginjaar HB (2010) Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients. Neuromuscular disorders: NMD 20:251–254
48. Himeda CL, Chen X, Hauschka SD (2011) Design and testing of regulatory cassettes for optimal activity in skeletal and cardiac muscles. Methods Mol Biol 709:3–19
49. Hoffman EP, Brown RH Jr, Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51:919–928
50. Hoffman EP, Kunkel LM, Angelini C, Clarke A, Johnson M, Harris JB (1989) Improved diagnosis of Becker muscular dystrophy by dystrophin testing. Neurology 39:1011–1017
51. Hollinger K, Chamberlain JS (2015) Viral vector-mediated gene therapies. Curr Opin Neurol 28:522–527
52. Hsu PD, Lander ES, Zhang F (2014) Development and applications of CRISPR-Cas9 for genome engineering. Cell 157:1262–1278
53. Iyombe-Engembe JP, Ouellet DL, Barbeau X, Rousseau J, Chapdelaine P, Lague P, Tremblay JP (2016) efficient restoration of the dystrophin gene reading frame and protein structure in DMD myoblasts using the CinDel method. Mol Ther Nucleic Acids 5:e283
54. Jin K, Sun Y, Xie L, Mao XO, Childs J, Peel A, Logvinova A, Banwait S, Greenberg DA (2005) Comparison of ischemia-directed migration of neural precursor cells after intrastriatal, intraventricular, or intravenous transplantation in the rat. Neurobiol Dis 18:366–374
55. Jirka S, Aartsma-Rus A (2015) An update on RNA-targeting therapies for neuromuscular disorders. Curr Opin Neurol 28:515–521
56. Joung JK, Sander JD (2013) TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 14:49–55
57. Kim D, Kim S, Kim S, Park J, Kim JS (2016) Genome-wide target specificities of CRISPR-Cas9 nucleases revealed by multiplex Digenome-seq. Genome Res 26:406–415
58. Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, Joung JK (2016) High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529:490–495
59. Kole R, Krieg AM (2015) Exon skipping therapy for Duchenne muscular dystrophy. Adv Drug Deliv Rev 87:104–107
60. Koo T, Okada T, Athanasopoulos T, Foster H, Takeda S, Dickson G (2011) Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog. J Gene Med 13:497–506
61. Koo T, Popplewell L, Athanasopoulos T, Dickson G (2014) Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice. Hum Gene Ther 25:98–108
62. Kornegay JN, Li J, Bogan JR, Bogan DJ, Chen C, Zheng H, Wang B, Qiao C, Howard JF Jr, Xiao X (2010) Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol Ther J Am Soc Gene Ther 18:1501–1508
63. Lapidos KA, Kakkar R, McNally EM (2004) The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res 94:1023–1031
64. Law PK, Goodwin TG, Fang Q, Duggirala V, Larkin C, Florendo JA, Kirby DS, Deering MB, Li HJ, Chen M et al (1992) Feasibility, safety, and efficacy of myoblast transfer therapy on Duchenne muscular dystrophy boys. Cell Transplant 1:235–244
65. Le Guiner C, Montus M, Servais L, Cherel Y, Francois V, Thibaud JL, Wary C, Matot B, Larcher T, Guigand L et al (2014) Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients. Mol Ther 22:1923–1935
66. Lee JJ, Yokota T (2013) Antisense therapy in neurology. J Personalized Med 3:144–176
67. Li H, Haurigot V, Doyon Y, Li T, Wong SY, Bhagwat AS, Malani N, Anguela XM, Sharma R, Ivanciu L et al (2011) In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 475:217–221
68. Li HL, Fujimoto N, Sasakawa N, Shirai S, Ohkame T, Sakuma T, Tanaka M, Amano N, Watanabe A, Sakurai H et al (2015) Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem cell reports 4:143–154
69. Liu MJ, Yue YP, Harper SQ, Grange RW, Chamberlain JS, Duan DS (2005) Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. Mol Ther 11:245–256
70. Long C, McAnally JR, Shelton JM, Mireault AA, Bassel-Duby R, Olson EN (2014) Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science 345:1184–1188
71. Long C, Amoasii L, Mireault AA, McAnally JR, Li H, Sanchez-Ortiz E, Bhattacharyya S, Shelton JM, Bassel-Duby R, Olson EN (2015) Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science. doi:10.1126/science.aad5725
72. Lostal W, Kodippili K, Yue Y, Duan D (2014) Full-length dystrophin reconstitution with adeno-associated viral vectors. Hum Gene Ther 25:552–562
73. Lu QL, Yokota T, Takeda S, Garcia L, Muntoni F, Partridge T (2011) The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy. Mol Ther 19:9–15
74. Madigan VJ, Asokan A (2016) Engineering AAV receptor footprints for gene therapy. Curr Opin Virol 18:89–96
75. Maeder ML, Gersbach CA (2016) Genome editing technologies for gene and cell therapy. Mol Ther. doi:10.1038/mt.2016.10
76. McClorey G, Wood MJ (2015) An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies. Curr Opin Pharmacol 24:52–58
77. McClorey G, Moulton HM, Iversen PL, Fletcher S, Wilton SD (2006) Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther 13:1373–1381
78. McCullagh KJ, Perlingeiro RC (2015) Coaxing stem cells for skeletal muscle repair. Adv Drug Deliv Rev 84:198–207
79. McDonald CM, Henricson EK, Abresch RT, Florence JM, Eagle M, Gappmaier E, Glanzman AM, Group PG-DS, Spiegel R, Barth J et al (2013) The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve 48:343–356
80. McDonald C, Henricson E, Abresch R, Han J, Nicorici A, Goude E, Elfring G, Reha A, Hirawat S, Miller L (2010a) The 6-Min walk test in duchenne muscular dystrophy: longitudinal observations. Neurology 74:A219–A219
81. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Elfring GL, Atkinson L, Reha A, Hirawat S, Miller LL (2010b) The 6-Minute Walk Test as a New Outcome Measure in Duchenne Muscular Dystrophy. Muscle Nerve 41:500–510
82. Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, Kaye EM, Mercuri E, Eteplirsen Study G, Telethon Foundation DMDIN (2016) Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Annals of neurology 79:257–271
83. Mendell JR, Kissel JT, Amato AA, King W, Signore L, Prior TW, Sahenk Z, Besson S, Mcandrew PE, Rice R et al (1995) Myoblast Transfer in the Treatment of Duchennes Muscular-Dystrophy. New Engl J Med 333:832–838
84. Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, Bowles D, Gray S, Li C, Galloway G et al (2010) Dystrophin immunity in Duchenne’s muscular dystrophy. N Engl J Med 363:1429–1437
85. Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, Alfano L, Gomez AM, Lewis S, Kota J et al (2013) Eteplirsen for the treatment of Duchenne muscular dystrophy. Annals of neurology 74:637–647
86. Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF, Meng X, Paschon DE, Leung E, Hinkley SJ et al (2011) A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 29:143–148
87. Naldini L (2015) Gene therapy returns to centre stage. Nature 526:351–360
88. Nallamilli BR, Ankala A, Hegde M. 2014. Molecular diagnosis of duchenne muscular dystrophy. Current protocols in human genetics/editorial board, Jonathan L Haines et al 83:9 25 21–29 25:29
89. Nelson CE, Gersbach CA (2016) Engineering delivery vehicles for genome editing. Annu Rev Chem Biomol Eng 7:637–662
90. Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Rivera RM, Madhavan S, Pan X, Ran FA, Yan WX et al (2015) In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science. doi:10.1126/science.aad5143
91. Ohshima S, Shin JH, Yuasa K, Nishiyama A, Kira J, Okada T, Takeda S (2009) Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. Mol Ther 17:73–80
92. Ousterout DG, Perez-Pinera P, Thakore PI, Kabadi AM, Brown MT, Qin X, Fedrigo O, Mouly V, Tremblay JP, Gersbach CA (2013) Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients. Mol Ther 21:1718–1726
93. Ousterout DG, Kabadi AM, Thakore PI, Majoros WH, Reddy TE, Gersbach CA (2015a) Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun 6:6244
94. Ousterout DG, Kabadi AM, Thakore PI, Perez-Pinera P, Brown MT, Majoros WH, Reddy TE, Gersbach CA (2015b) Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases. Mol Ther J Am Soc Gene The 23:523–532
95. Palmieri B, Tremblay JP, Daniele L (2010) Past, present and future of myoblast transplantation in the treatment of Duchenne muscular dystrophy. Pediatr Transplant 14:813–819
96. Pane M, Mazzone ES, Sivo S, Sormani MP, Messina S, D’Amico A, Carlesi A, Vita G, Fanelli L, Berardinelli A et al (2014) Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes. PLoS One 9:e108205
97. Parker AE, Robb SA, Chambers J, Davidson AC, Evans K, O’Dowd J, Williams AJ, Howard RS (2005) Analysis of an adult Duchenne muscular dystrophy population. QJM Monthly J Assoc Physicians 98:729–736
98. Penaud-Budloo M, Le Guiner C, Nowrouzi A, Toromanoff A, Cherel Y, Chenuaud P, Schmidt M, von Kalle C, Rolling F, Moullier P et al (2008) Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle. J Virol 82:7875–7885
99. Popplewell L, Koo T, Leclerc X, Duclert A, Mamchaoui K, Gouble A, Mouly V, Voit T, Paques F, Cedrone F et al (2013) Gene correction of a duchenne muscular dystrophy mutation by meganuclease-enhanced exon knock-in. Hum Gene Ther 24:692–701
100. Quenneville SP, Chapdelaine P, Rousseau J, Beaulieu J, Caron NJ, Skuk D, Mills P, Olivares EC, Calos MP, Tremblay JP (2004) Nucleofection of muscle-derived stem cells and myoblasts with phiC31 integrase: stable expression of a full-length-dystrophin fusion gene by human myoblasts. Mol Ther J Am Soc Gene Ther 10:679–687
101. Ramos J, Chamberlain JS (2015) Gene therapy for duchenne muscular dystrophy. Expert Opinion Orphan Drugs 3:1255–1266
102. Ricotti V, Ridout DA, Scott E, Quinlivan R, Robb SA, Manzur AY, Muntoni F, NorthStar Clinical N (2013) Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 84:698–705
103. Romero NB, Braun S, Benveniste O, Leturcq F, Hogrel JY, Morris GE, Barois A, Eymard B, Payan C, Ortega V et al (2004) Phase I study of dystrophin Duchenne/Becker plasmid-based gene therapy in muscular dystrophy. Hum Gene Ther 15:1065–1076
104. Sazani P, Weller DL, Shrewsbury SB (2010) Safety pharmacology and genotoxicity evaluation of AVI-4658. Int J Toxicol 29:143–156
105. Sazani P, Ness KP, Weller DL, Poage D, Nelson K, Shrewsbury AS (2011a) Chemical and mechanistic toxicology evaluation of exon skipping phosphorodiamidate morpholino oligomers in mdx mice. Int J Toxicol 30:322–333
106. Sazani P, Ness KP, Weller DL, Poage DW, Palyada K, Shrewsbury SB (2011b) Repeat-dose toxicology evaluation in cynomolgus monkeys of AVI-4658, a phosphorodiamidate morpholino oligomer (PMO) drug for the treatment of duchenne muscular dystrophy. Int J Toxicol 30:313–321
107. Sebastiano V, Maeder ML, Angstman JF, Haddad B, Khayter C, Yeo DT, Goodwin MJ, Hawkins JS, Ramirez CL, Batista LF et al (2011) In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases. Stem Cells 29:1717–1726
108. Shin JH, Pan X, Hakim CH, Yang HT, Yue Y, Zhang K, Terjung RL, Duan D (2013) Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy. Mol Ther 21:750–757
109. Silva G, Poirot L, Galetto R, Smith J, Montoya G, Duchateau P, Paques F (2011) Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy. Curr Gene Ther 11:11–27
110. Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F (2016) Rationally engineered Cas9 nucleases with improved specificity. Science 351:84–88
111. Tabebordbar M, Zhu K, Cheng JK, Chew WL, Widrick JJ, Yan WX, Maesner C, Wu EY, Xiao R, Ran FA et al (2015) In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science. doi:10.1126/science.aad5177
112. Touznik A, Lee JJ, Yokota T (2014) New developments in exon skipping and splice modulation therapies for neuromuscular diseases. Expert Opin Biol Therapy 14:809–819
113. Tremblay JP, Malouin F, Roy R, Huard J, Bouchard JP, Satoh A, Richards CL (1993) Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy. Cell Transplant 2:99–112
114. Tsai SQ, Zheng Z, Nguyen NT, Liebers M, Topkar VV, Thapar V, Wyvekens N, Khayter C, Iafrate AJ, Le LP et al (2015) GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol 33:187–197
115. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD (2010) Genome editing with engineered zinc finger nucleases. Nat Rev Genet 11:636–646
116. van Westering TL, Betts CA, Wood MJ (2015) Current understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophy. Molecules 20:8823–8855
117. Voit T, Topaloglu H, Straub V, Muntoni F, Deconinck N, Campion G, De Kimpe SJ, Eagle M, Guglieri M, Hood S et al (2014) Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol 13:987–996
118. Vulin A, Barthelemy I, Goyenvalle A, Thibaud JL, Beley C, Griffith G, Benchaouir R, le Hir M, Unterfinger Y, Lorain S et al (2012) Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. Mol Ther 20:2120–2133
119. Wagner KR, Lechtzin N, Judge DP (2007) Current treatment of adult Duchenne muscular dystrophy. Biochim Biophys Acta 1772:229–237
120. Wang B, Li J, Xiao X (2000) Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci USA 97:13714–13719
121. Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J, Chen C, Li J, Xiao X (2005) Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 23:321–328
122. Wang B, Li J, Fu FH, Xiao X (2009) Systemic human minidystrophin gene transfer improves functions and life span of dystrophin and dystrophin/utrophin-deficient mice. J Orthop Res 27:421–426
123. Watchko J, O’Day T, Wang B, Zhou LQ, Tang Y, Li J, Xiao X (2002) Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. Hum Gene Ther 13:1451–1460
124. Wein N, Vulin A, Falzarano MS, Szigyarto CA, Maiti B, Findlay A, Heller KN, Uhlen M, Bakthavachalu B, Messina S et al (2014) Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice. Nat Med 20:992–1000
125. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S et al (2007) PTC124 targets genetic disorders caused by nonsense mutations. Nature 447:87–91
126. Wu B, Moulton HM, Iversen PL, Jiang J, Li J, Spurney CF, Sali A, Guerron AD, Nagaraju K, Doran T et al (2008) Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci USA 105:14814–14819
127. Xu L, Park KH, Zhao L, Xu J, El Refaey M, Gao Y, Zhu H, Ma J, Han R (2015) CRISPR-mediated genome editing restores dystrophin expression and function in mdx mice. Mol Ther. doi:10.1038/mt.2015.192
128. Yin H, Moulton HM, Seow Y, Boyd C, Boutilier J, Iverson P, Wood MJ (2008) Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 17:3909–3918
129. Yokota T, Lu QL, Partridge T, Kobayashi M, Nakamura A, Takeda S, Hoffman E (2009) Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 65:667–676
130. Yoshimura M, Sakamoto M, Ikemoto M, Mochizuki Y, Yuasa K, Miyagoe-Suzuki Y, Takeda S (2004) AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype. Mol Ther J Am Soc Gene Ther 10:821–828
131. Young CS, Hicks MR, Ermolova NV, Nakano H, Jan M, Younesi S, Karumbayaram S, Kumagai-Cresse C, Wang D, Zack JA et al (2016) A single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-derived muscle cells. Cell Stem Cell. doi:10.1016/j.stem.2016.01.021
132. Yue YP, Li ZB, Harper SQ, Davisson RL, Chamberlain JS, Duan DS (2003) Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation 108:1626–1632
133. Zhang G, Ludtke JJ, Thioudellet C, Kleinpeter P, Antoniou M, Herweijer H, Braun S, Wolff JA (2004) Intraarterial delivery of naked plasmid DNA expressing full-length mouse dystrophin in the mdx mouse model of duchenne muscular dystrophy. Hum Gene Ther 15:770–782
134. Zou J, Mali P, Huang X, Dowey SN, Cheng L (2011) Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 118:4599–4608